In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was $17.21 for the day, up 3.67% from the previous closing price of $16.6. In other words, the price has increased by $3.67 from its previous closing price. On the day, 9.83 million shares were traded. TEVA stock price reached its highest trading level at $17.28 during the session, while it also had its lowest trading level at $16.672.
Ratios:
Our analysis of TEVA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.61. For the most recent quarter (mrq), Quick Ratio is recorded 0.77 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 2.57 whereas as Long-Term Debt/Eq ratio is at 2.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On May 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $25.
JP Morgan Upgraded its Neutral to Overweight on May 12, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 01 ’25 when Jover Placid sold 6,053 shares for $15.16 per share. The transaction valued at 91,748 led to the insider holds 6,774 shares of the business.
Hughes Eric A sold 52,742 shares of TEVA for $799,437 on Aug 01 ’25. The See “Remarks” now owns 0 shares after completing the transaction at $15.16 per share. On Aug 01 ’25, another insider, Jover Placid, who serves as the Officer of the company, bought 6,053 shares for $15.16 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 19742449664 and an Enterprise Value of 35130466304. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.18 while its Price-to-Book (P/B) ratio in mrq is 2.89. Its current Enterprise Value per Revenue stands at 2.113 whereas that against EBITDA is 7.769.
Stock Price History:
The Beta on a monthly basis for TEVA is 0.72, which has changed by -0.061102033 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, TEVA has reached a high of $22.80, while it has fallen to a 52-week low of $12.47. The 50-Day Moving Average of the stock is 3.09%, while the 200-Day Moving Average is calculated to be -0.02%.
Shares Statistics:
TEVA traded an average of 11.31M shares per day over the past three months and 12531240 shares per day over the past ten days. A total of 1.15B shares are outstanding, with a floating share count of 1.15B. Insiders hold about 0.01% of the company’s shares, while institutions hold 64.54% stake in the company. Shares short for TEVA as of 1753920000 were 49888340 with a Short Ratio of 4.41, compared to 1751241600 on 39866309. Therefore, it implies a Short% of Shares Outstanding of 49888340 and a Short% of Float of 4.37.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0The stock’s 5-year Average Dividend Yield is 2.95.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) in the stock market.The consensus estimate for the next quarter is $0.71, with high estimates of $0.74 and low estimates of $0.65.
Analysts are recommending an EPS of between $2.62 and $2.51 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.77, with 11.0 analysts recommending between $2.88 and $2.64.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $4.42B to a low estimate of $4.3B. As of the current estimate, Teva- Pharmaceutical Industries Ltd. ADR’s year-ago sales were $4.33BFor the next quarter, 7 analysts are estimating revenue of $4.45B. There is a high estimate of $4.64B for the next quarter, whereas the lowest estimate is $4.29B.
A total of 10 analysts have provided revenue estimates for TEVA’s current fiscal year. The highest revenue estimate was $17.05B, while the lowest revenue estimate was $16.78B, resulting in an average revenue estimate of $16.9B. In the same quarter a year ago, actual revenue was $16.54BBased on 10 analysts’ estimates, the company’s revenue will be $16.98B in the next fiscal year. The high estimate is $17.15B and the low estimate is $16.69B.
